InsightsFinance & Performance

The Economist once priced a subscription nobody was supposed to buy.

By Uttam Dinodia2 min readView this post on LinkedIn

That option quietly sold everything else.

Three options. Web for $59. Print for $125. Print and web, also $125.

The middle one looks absurd. Why pay $125 for print alone when print and web cost the same?

That was the point.

Dan Ariely tested it on 100 students. With the print-only option in place, 84% took the bundle, 16% took web, and nobody took print alone. Remove it, and most switched to the cheap $59 plan. Revenue in the test fell by roughly 43%.

The option nobody chose was doing the selling.

Joel Huber, John Payne and Christopher Puto named this in the Journal of Consumer Research in 1982. The asymmetric dominance effect: place a third choice clearly worse than the one you want bought, and preference shifts towards it. People read value by comparison, rarely in absolute terms.

Marn and Rosiello showed in Harvard Business Review (1992) that a 1% improvement in price, with no volume lost, lifts operating profit by around 11%, three to four times the gain from selling more units. Few business decisions move profit that fast.

But the effect is fragile. Frederick, Lee and Baskin found in 2014 that it weakens, vanishes, or even reverses once options carry real brands and messy detail rather than two clean numbers. Researchers call the backfire a repulsion effect: a clumsy decoy taints the comparison and pushes buyers to the cheap end instead.

The same logic sits inside any tender. A weak third bid quietly anchors how evaluators read the other two. The defence is dull and rarely used: score each option against the specification you actually need, never against the option sitting beside it.

So look at your own pricing sheet, or the next proposal you put in front of a buyer. Which option is built to win, and which is built to make it win?

Uttam Dinodia

Uttam Dinodia

Pharmaceutical Business Consultant & Executive Director, A One Afro Limited

Over 22 years in pharmaceutical supply. Helps international manufacturers and Zambian institutions with public tenders, ZAMRA regulatory pathways and distribution.